MindMed prices $75M public offering of common shares and pre-funded warrants; cash position $243.1M

Definium Therapeutics, Inc.

Underwritten public offering of 9,285,511 common shares at $7.00/share and 1,428,775 pre-funded warrants at $6.999/warrant.
Gross proceeds of ~$75M; net proceeds of ~$70M after underwriting discounts and expenses.
Preliminary cash and cash equivalents of ~$243.1M as of June 30, 2024, disclosed in prospectus supplement.
Offering expected to close on August 12, 2024; net proceeds to fund R&D and working capital.
Leerink Partners and Evercore ISI acting as joint bookrunning managers; RBC and Oppenheimer as lead managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.